Drug Discovery

Vineti, Tessa partner to advance cancer immunotherapies

Vineti has entered into a new partnership with Tessa Therapeutics to advance and scale personalized cell therapies for solid tumors in Asia and world-wide.

Evotec, Immuneering partner on AI-driven approach to ligand identification

Evotec has entered into a research collaboration with Immuneering on artificial intelligence (AI) driven ligand identification for rare hereditary metabolic diseases.

LEO Pharma, PellePharm form $760m rare skin disease collaboration

LEO Pharma and PellePharm have entered into a development and commercialization collaboration to address unmet medical needs in various skin diseases like Gorlin Syndrome and High Frequency Basal Cell Carcinoma (BCC).

Boehringer, Epizyme announce $300m oncology therapy program

Boehringer Ingelheim has entered into a new global collaboration with Epizyme to develop novel epigenetic oncology therapies.

Scientists engineer DNA-encoded monoclonal antibodies targeting Zaire Ebolavirus

Scientists at The Wistar Institute and collaborators have engineered novel DNA-encoded monoclonal antibodies (DMAbs) targeting Zaire Ebolavirus that were effective in preclinical models.

Biopharmaceutical firm NextCure completes $93m series B equity financing

NextCure, a biopharmaceutical firm engaged in the discovery and development of next generation immunomedicines for cancer and other diseases, has raised $93m in Series B financing.

CRISPR, MaxCyte expand partnership into immuno-oncology

Gene editing company CRISPR Therapeutics and cell-based medicines and life sciences firm MaxCyte have expanded clinical and commercial license agreement into oncology.

Nestlé Health Science increases stake in Aimmune Therapeutics

Nestlé Health Science has increased its stake in biopharmaceutical firm Aimmune Therapeutics by making an additional equity investment of $98m.

Harpoon raises $70m financing to advance immunotherapy programs

Harpoon Therapeutics, a clinical-stage immunotherapy company engaged in the development of a class of T cell engagers, has completed $70m series C equity financing.